BRPI0407311A - composições compreendendo hemoglobina fetal e endotoxina bacterial e opcionalmente adição de componentes fetais, do fìgado - Google Patents

composições compreendendo hemoglobina fetal e endotoxina bacterial e opcionalmente adição de componentes fetais, do fìgado

Info

Publication number
BRPI0407311A
BRPI0407311A BRPI0407311-8A BRPI0407311A BRPI0407311A BR PI0407311 A BRPI0407311 A BR PI0407311A BR PI0407311 A BRPI0407311 A BR PI0407311A BR PI0407311 A BRPI0407311 A BR PI0407311A
Authority
BR
Brazil
Prior art keywords
fetal
composition
endotoxin
fetal hemoglobin
hemoglobin
Prior art date
Application number
BRPI0407311-8A
Other languages
English (en)
Inventor
Westphal Otto
Original Assignee
Clinique La Prairie Res S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinique La Prairie Res S A filed Critical Clinique La Prairie Res S A
Publication of BRPI0407311A publication Critical patent/BRPI0407311A/pt
Publication of BRPI0407311B1 publication Critical patent/BRPI0407311B1/pt
Publication of BRPI0407311B8 publication Critical patent/BRPI0407311B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO COMPREENDENDO HEMOGLOBINA FETAL E ENDOTOXINA BACTERIALE OPCIONALMENTE ADIçãO DE COMPONENTES FETAIS DO FìGADO". A presente invenção trata de uma composição farmacêutica representando um novo princípio imunomodular compreendendo uma endotoxina bacterial, hemoglobina fetal ou, mais particularmente, um derivado de heme-livre ou da cadeia-(sym) e, opcionalmente, componentes que estão presentes no fígado fetal em adição à HbF. A composição é oportunizada ao homem em um portador farmacêutico e/ou diluente. De acordo com a presente invenção, foi surpreendentemente percebido que a endotoxina e a estrutura da hemoglobina fetal apresentam uma atividade sinergética biomédica. Os efeitos biomédicos da hemoglobina fetal e sua estrutura parcial não são, surpreendentemente, baseados na clássica função da hemoglobina, transportadora de oxigênio, mas relacionada à bioatividade modular da endotoxina intermediária. Esta atividade biomédica é também, surpreendentemente, observada depois da aplicação oral da composição. A composição da invenção encontra uma variedade de aplicações que tem em comum a estimulação do sistema imunológico e a reversão na polarização das citocinas e quemocina da resposta direta do Th2 para a resposta do tipo Th1. As aplicações propostas, portanto, incluiriam o tratamento de condições alérgicas, malignidades, infecções crónicas, fenómeno autoimune a desestabilizações relacionadas à idade.
BRPI0407311A 2003-02-18 2004-02-18 Composições compreendendo hemoglobina fetal e endotoxina bacterial e opcionalmente adição de componentes fetais, do fígado BRPI0407311B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03003687A EP1449535B1 (en) 2003-02-18 2003-02-18 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components
EP03003687.5 2003-02-18
PCT/EP2004/001553 WO2004073728A2 (en) 2003-02-18 2004-02-18 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components

Publications (3)

Publication Number Publication Date
BRPI0407311A true BRPI0407311A (pt) 2006-02-21
BRPI0407311B1 BRPI0407311B1 (pt) 2020-12-29
BRPI0407311B8 BRPI0407311B8 (pt) 2021-11-30

Family

ID=32731533

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407311A BRPI0407311B8 (pt) 2003-02-18 2004-02-18 Composições compreendendo hemoglobina fetal e endotoxina bacterial e opcionalmente adição de componentes fetais, do fígado

Country Status (20)

Country Link
US (1) US7968103B2 (pt)
EP (2) EP1449535B1 (pt)
JP (1) JP4619352B2 (pt)
KR (1) KR101102481B1 (pt)
CN (1) CN1750840A (pt)
AT (1) ATE324903T1 (pt)
AU (1) AU2004212703C1 (pt)
BR (1) BRPI0407311B8 (pt)
CA (1) CA2514485C (pt)
DE (1) DE60304989T2 (pt)
DK (1) DK1449535T3 (pt)
ES (1) ES2263859T3 (pt)
IL (1) IL169760A (pt)
IS (1) IS2294B (pt)
MX (1) MXPA05008797A (pt)
NO (1) NO334003B1 (pt)
NZ (1) NZ541417A (pt)
PL (1) PL211789B1 (pt)
RU (1) RU2366449C2 (pt)
WO (1) WO2004073728A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103427A2 (en) * 2006-03-06 2007-09-13 Wang Xiang H Medical use of bilirubin and its structural analogues
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2010006200A2 (en) * 2008-07-09 2010-01-14 Board Of Regents, The University Of Texas System Triggered release of drugs from polymer particles
WO2010123798A2 (en) 2009-04-20 2010-10-28 Galenbio, Inc. Compositions for transfection of biomolecules into cells
EP2789343A1 (en) * 2013-04-11 2014-10-15 Clinique La Prairie Novel hemoglobin-derived peptide based pharmaceutical compositions
EP3019186A4 (en) * 2013-07-12 2017-03-29 Patrick J. Casey Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473647A (en) * 1981-02-27 1984-09-25 Amf Inc. Tissue culture medium
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
EP0271521A4 (en) 1986-05-09 1989-11-14 Sloan Kettering Inst Cancer Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment.
ATE126698T1 (de) 1989-06-30 1995-09-15 American Cyanamid Co Verwendung eines phagozytise-aktievierenden stoffes : lps oder il-2 zur herstellung eines arzneimittels zur behandlung von staphylococcus- aureus-infektionen bei kühen.
EP0472467A3 (en) 1990-08-20 1993-03-17 Chiba Flour Milling Co. Ltd. Lps-containing analgesics and veterinary analgesics
JPH0499481A (ja) * 1990-08-20 1992-03-31 Chiba Seifun Kk 新規細菌、新規ｌｐｓ、新規免疫機能活性化剤、新規動物用免疫機能活性化剤
JPH0690745A (ja) * 1990-08-20 1994-04-05 Chiba Seifun Kk Ｌｐｓ産生菌、ｌｐｓ、ｌｐｓを含む医薬及び動物薬
JPH04187640A (ja) * 1990-11-22 1992-07-06 Chiba Seifun Kk 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤
DE539610T1 (de) * 1991-10-26 1993-12-16 Torf Ets Verfahren und Zusammensetzung zur Bestimmung der Immunologischen Aktivität von aktiven Substanzen enthaltende Lösungen.
JP3199081B2 (ja) * 1992-11-13 2001-08-13 味の素株式会社 抗腫瘍剤
DE4338812A1 (de) * 1993-11-15 1995-05-18 Braun Melsungen Ag Verwendung von Lösungen von vernetztem Hämoglobin zur Bekämpfung des septischen und hämorrhagischen Schocks bei Säugetieren
US5648343A (en) * 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
US5580724A (en) * 1994-03-25 1996-12-03 Board Of Regents, The University Of Texas System Differential expansion of fetal stem cells in maternal circulation for use in prenatal genetic analysis
US20020065211A1 (en) * 1995-03-23 2002-05-30 Biopure Corporation Increasing function of organs having reduced red blood cell flow
DK0863866T3 (da) 1995-10-06 2001-06-11 Vertex Pharma Butyrat-prodrugs afledt af mælkesyre
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
EP0856592A1 (en) 1997-02-04 1998-08-05 N.V. Bekaert S.A. A coating comprising layers of diamond like carbon and diamond like nanocomposite compositions
JP4256938B2 (ja) * 1997-02-04 2009-04-22 ナムローゼ・フェンノートシャップ・ベーカート・ソシエテ・アノニム ダイヤモンド状カーボン及びダイヤモンド状ナノコンポジット組成物の層を有するコーティング物
RU2140283C1 (ru) * 1998-12-15 1999-10-27 Товарищество с ограниченной ответственностью "Биотех" Фармацевтический препарат на основе интерлейкина-2 (варианты)
EP2292657A1 (en) * 1999-11-12 2011-03-09 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
EP2295968B1 (en) * 1999-12-03 2012-09-19 Baxter International Inc. Pyrogenicity test for use with automated immunoassay systems
US20010026800A1 (en) * 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
WO2002017965A1 (en) * 2000-08-28 2002-03-07 Akira Awaya Medicinal compositions
DE10103211C1 (de) * 2001-01-24 2002-07-18 Ursula Kastner Kulturmedium

Also Published As

Publication number Publication date
IS2294B (is) 2007-10-15
NZ541417A (en) 2008-08-29
BRPI0407311B8 (pt) 2021-11-30
KR20050111596A (ko) 2005-11-25
IS7940A (is) 2005-07-18
IL169760A (en) 2012-09-24
RU2005126141A (ru) 2006-01-27
KR101102481B1 (ko) 2012-01-05
WO2004073728A3 (en) 2004-10-07
WO2004073728A2 (en) 2004-09-02
EP1449535B1 (en) 2006-05-03
AU2004212703C1 (en) 2009-05-21
EP1449535A1 (en) 2004-08-25
PL378573A1 (pl) 2006-05-02
US20080075742A1 (en) 2008-03-27
US7968103B2 (en) 2011-06-28
NO20054087L (no) 2005-11-08
NO20054087D0 (no) 2005-09-02
DE60304989D1 (de) 2006-06-08
AU2004212703B2 (en) 2008-10-30
BRPI0407311B1 (pt) 2020-12-29
AU2004212703A1 (en) 2004-09-02
NO334003B1 (no) 2013-11-11
DE60304989T2 (de) 2007-03-29
EP1601371A2 (en) 2005-12-07
RU2366449C2 (ru) 2009-09-10
CN1750840A (zh) 2006-03-22
CA2514485C (en) 2013-11-05
PL211789B1 (pl) 2012-06-29
JP2006518350A (ja) 2006-08-10
DK1449535T3 (da) 2006-09-11
JP4619352B2 (ja) 2011-01-26
ES2263859T3 (es) 2006-12-16
CA2514485A1 (en) 2004-09-02
MXPA05008797A (es) 2006-05-25
ATE324903T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
BR0010682A (pt) Novas composições
BRPI0515316A (pt) compostos de imidazoquinolina
ECSP045154A (es) Composiciones de fórmula para infantes que comrende cantidades aumentadas de alfa - lactalbumin
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
MXPA05009933A (es) Composiciones que comprenden acidos grasos y aminoacidos.
HUP0401144A2 (hu) Enterális tápszerkészítmények
BR0008059A (pt) Composições de valdecoxib
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BR9714349A (pt) L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
ATE245977T1 (de) Therapeutische substituierte guanidine
BR0315169A (pt) Referência cruzada a pedidos de patente relacionados
ATE411032T1 (de) Verwendungen von chitosanoligosacchariden
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
BR9702200A (pt) Compostos bicíclicos-aromáticos composição farmacéutica composição cosmética e utilização de uma composição cosmética
KR870700599A (ko) 카르복실산유도체, 그의 제조방법, 이화합물을 함유한 약제조성물 및 그의 용도
NO20076405L (no) Anvendelse av 24-nor-UDCA
BRPI0407311A (pt) composições compreendendo hemoglobina fetal e endotoxina bacterial e opcionalmente adição de componentes fetais, do fìgado
BRPI0416376A (pt) composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes
BRPI0507895A (pt) composição para o tratamento de insuficiências venosas crÈnicas, compreendendo um extrato de folhas de videira-vermelha e um agente antiinflamatório
BR0309421A (pt) Composições de proteìna associada com corpo oleoso e métodos de uso destas para reduzir o risco de doença cardiovascular
HUP0301506A2 (hu) Gyógyászati készítmények nedves hámfelületek fájdalmas, gyulladásos vagy fekélyes állapotai, így például nyálkahártyagyulladás, szájgyulladás és behcet-tünetcsoport kezelésére
BRPI0408848A (pt) formulações orais de cladribine
DE60307665D1 (de) Haarbehandlungszusammensetzungen mit xanthin und alpha-hydroxysäure
BRPI0418224A (pt) composição que compreende um extrato aquoso de folhas de videira-vermelha e um agente antitrombótico para o tratamento de insuficiências venosas crÈnicas
BRPI9916549B8 (pt) Composição farmacêutica, proteína, polinucleotídeo

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: CLINIQUE LA PRAIRIE RESEARCH S.A (LU)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 016110003909/RS DE 25/07/2011, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO DEVIDAMENTE NOTARIZADO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: CLINIQUE LA PRAIRIE RESEARCH S.A (LU)

Free format text: ANULADA A EXIGENCIA PUBILCADA NA RPI NO 2137, DE 20/12/2011, POR FALTA DE FUNDAMENTACAO LEGAL.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: CLINIQUE LA PRAIRIE RESEARCH S.A (LU)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 016110003909/RS DE 25/07/2011, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO NOTARIZADO E COM A DEVIDA LEGALIZACAO CONSULAR, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25B Requested transfer of rights rejected

Owner name: CLINIQUE LA PRAIRIE RESEARCH S.A (LU)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 16110003909/RS DE 25/07/2011, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2294, DE 23/12/2014.

B25A Requested transfer of rights approved

Owner name: CLINIQUE LA PRAIRIE FRANCHISING S.A. (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/02/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: CLINIQUE LA PRAIRIE SA (CH)

B25G Requested change of headquarter approved

Owner name: CLINIQUE LA PRAIRIE SA (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2608 DE 29/12/2020 QUANTO AO TITULAR E O ENDERECO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2822 DE 04/02/2025 POR TER SIDO INDEVIDA.